Analyst Price Target is $10.00
▲ +1,349.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vincerx Pharma in the last 3 months. The average price target is $10.00, with a high forecast of $28.00 and a low forecast of $3.00. The average price target represents a 1,349.49% upside from the last price of $0.69.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Vincerx Pharma.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.